STOCK TITAN

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Akebia Therapeutics® (Nasdaq: AKBA) will release its financial results for Q3 2023 on November 8th. A conference call will be held on the same day at 8:00 a.m. ET to discuss the results and recent business highlights.
Positive
  • None.
Negative
  • None.

Akebia to Host Conference Call on November 8th at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023, prior to the open of financial markets.

Akebia will host a conference call on Wednesday, November 8 at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Registration Link and you will be provided with dial in details. To avoid delays, we encourage dialing into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-third-quarter-2023-financial-results-and-discuss-recent-business-highlights-301972671.html

SOURCE Akebia Therapeutics

FAQ

When will Akebia Therapeutics release its financial results for Q3 2023?

Akebia Therapeutics will release its financial results for Q3 2023 on November 8th.

What is the stock symbol for Akebia Therapeutics?

The stock symbol for Akebia Therapeutics is AKBA.

When is the conference call to discuss the financial results?

The conference call to discuss the financial results will be held on November 8th at 8:00 a.m. ET.

Where can I access the conference call?

You can access the conference call by clicking on the Registration Link provided in the press release.

Is there a webcast available for the conference call?

Yes, a live webcast of the conference call will be available on the Investors section of Akebia's website at https://ir.akebia.com/.

Akebia Therapeutics, Inc.

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Stock Data

272.47M
188.22M
2.47%
26.27%
6.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.